BeiGene Ltd (BGNE)
162.25
+0.24
(+0.15%)
USD |
NASDAQ |
May 03, 16:00
161.97
-0.28
(-0.17%)
After-Hours: 20:00
BeiGene Revenue (Quarterly): 634.41M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 634.41M |
| September 30, 2023 | 781.31M |
| June 30, 2023 | 595.26M |
| March 31, 2023 | 447.80M |
| December 31, 2022 | 380.10M |
| September 30, 2022 | 387.63M |
| June 30, 2022 | 341.57M |
| March 31, 2022 | 306.63M |
| December 31, 2021 | 213.98M |
| September 30, 2021 | 206.44M |
| June 30, 2021 | 149.99M |
| March 31, 2021 | 605.87M |
| December 31, 2020 | 100.10M |
| September 30, 2020 | 91.08M |
| June 30, 2020 | 65.64M |
| March 31, 2020 | 52.06M |
| December 31, 2019 | 56.89M |
| September 30, 2019 | 50.14M |
| June 30, 2019 | 243.35M |
| Date | Value |
|---|---|
| March 31, 2019 | 77.83M |
| December 31, 2018 | 58.67M |
| September 30, 2018 | 54.20M |
| June 30, 2018 | 52.80M |
| March 31, 2018 | 32.54M |
| December 31, 2017 | 18.17M |
| September 30, 2017 | 220.21M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | 0.393M |
| March 31, 2016 | 0.677M |
| December 31, 2015 | 4.677M |
| September 30, 2015 | 1.38M |
| June 30, 2015 | 1.38M |
| March 31, 2015 | 1.379M |
| December 31, 2014 | 1.381M |
| September 30, 2014 | 6.496M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
50.14M
Minimum
Sep 2019
781.31M
Maximum
Sep 2023
300.54M
Average
243.35M
Median
Jun 2019
Revenue (Quarterly) Benchmarks
| Theravance Biopharma Inc | 17.56M |
| LumiraDx Ltd | 21.00M |
| Dr Reddy's Laboratories Ltd | 866.49M |
| ASLAN Pharmaceuticals Ltd | -- |
| Zai Lab Ltd | 65.83M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -367.55M |
| Total Expenses (Quarterly) | 1.018B |
| EPS Diluted (Quarterly) | -3.51 |
| Enterprise Value | 14.64B |
| Gross Profit Margin (Quarterly) | 83.32% |
| Profit Margin (Quarterly) | -57.94% |
| Earnings Yield | -5.29% |
| Normalized Earnings Yield | -5.288 |